Marker Therapeutics, Inc., a clinical-stage immunotherapy company, is making strides in the development and commercialization of T cell-based immunotherapies for the treatment of various types of cancer in the United States. The company's MultiTAA-specific T cell technology relies on the production of non-engineered tumor-specific T cells that are capable of recognizing and attacking multiple tumor-associated antigens. Among its portfolio of MultiTAA-specific T cell therapies are autologous T cells for treating lymphoma and select solid tumors, as well as allogeneic T cells for treating acute myeloid leukemia and acute lymphoblastic leukemia. It is also working on off-the-shelf products for various indications. Currently, Marker Therapeutics is in the middle of Phase 2 clinical trials for MT-401, a treatment for post-transplant AML; MT-401-OTS, AML; and MT-601, pancreatic cancer, and lymphoma. The company was established in 1999 and has been based in Houston, Texas ever since.